查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1970812

萘普生市場－全球產業規模、佔有率、趨勢、機會、預測：按應用、銷售管道、地區和競爭格局分類，2021-2031年

Naproxen Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By End-Use Application, By Sales Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球萘普生市場預計將從 2025 年的 2.2782 億美元成長到 2031 年的 3.5061 億美元，複合年成長率為 7.45%。

萘普生是非類固醇消炎劑(NSAID)，主要用於緩解肌腱炎和關節炎等肌肉骨骼疾病引起的發燒、發炎和疼痛。慢性疼痛疾病在全球範圍內的日益普遍以及人口老化的快速發展，都推動了萘普生市場的成長，因為人們對可靠的止痛藥的需求日益迫切。此外，萘普生經濟實惠，且在非處方藥和處方藥兩種管道均有銷售，也進一步促進了其市場成長。根據美國疾病管制與預防中心 (CDC) 預測，到 2024 年，美國約有五分之一的成年人將患有關節炎，這凸顯了有效疼痛管理方案的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 2.2782億美元
市場規模：2031年 3.5061億美元
複合年成長率：2026-2031年 7.45%
成長最快的細分市場 直銷
最大的市場 北美洲

然而，儘管市場表現強勁，但長期使用帶來的不良健康影響仍構成重大挑戰。胃腸道毒性和心血管併發症等嚴重問題仍然存在，這些風險因素降低了患者的依從性，並限制了藥物的長期效用。反過來，這些安全問題也為其他治療領域挑戰萘普生的市場地位創造了機會。

市場促進因素

慢性發炎性疾病和肌肉骨骼疾病發生率的上升是全球萘普生市場的主要驅動力。萘普生廣泛用於治療僵直性脊椎炎和骨關節炎等疾病，其緩解僵硬和發炎的卓越療效已得到證實。此外，持續存在的下背痛問題需要長期有效的治療策略，這也進一步推高了萘普生的需求。根據2025年1月發表在《BMC肌肉骨骼疾病》雜誌上的一篇題為「55歲及以上成年人腰痛的全球、區域和國家負擔」的論文，全球約有2.717億55歲及以上成年人患有腰痛。如此巨大的負擔直接推動了處方藥和非處方藥的穩定銷售量，因為患者需要可靠的緩解方法。

同時，由於老年人關節退化風險增加，全球老年人口迅速成長，這是推動市場擴張的關鍵因素。隨著預期壽命的延長，需要接受老齡化相關疾病維持治療的患者人數不斷增加，鞏固了萘普生作為重要治療選擇的地位。根據聯合國於2024年7月發布的《2024年世界人口展望》報告，全球整體65歲以上人口將達到約8.3億，構成龐大的病患群體。這一人口趨勢也轉化為實際的財務表現。例如，拜耳公司於2024年11月發布的《2024年第三季財務業績報告》顯示，其消費者健康部門「疼痛與心血管」類別的銷售額成長了10.9%，凸顯了市場對鎮痛產品的強勁需求。

市場挑戰

由於長期使用萘普生存在已知的健康風險，特別是心血管併發症和胃腸道毒性，全球萘普生市場面臨許多挑戰。這種安全性限制了該藥物在慢性肌肉骨骼疾病長期治療中的應用，並直接阻礙了市場成長。因此，醫療服務提供者變得更加謹慎，限制劑量和療程以最大程度地減少潛在危害，導致萘普生處方總量下降。此外，患者本身也越來越關注這些嚴重的副作用，導致用藥依從性降低，對非藥物療法和替代止痛藥的需求增加。

目前的臨床數據進一步證實了風險等級與劑量之間的相關性，從而支持了這種謹慎態度。根據歐洲抗風濕病聯盟 (EULAR) 2024 年的報告，與低劑量使用相比，高劑量使用非類固醇抗發炎藥物 (NSAIDs) 會使心血管疾病風險增加 10%。這些發現凸顯了這些藥物存在重大的安全隱患，限制了其商業性潛力，迫使醫療專業人員仔細權衡治療效益與風險。因此，長期疼痛管理領域的收入成長受到抑制。

市場趨勢

市場上，臨床治療通訊協定正明顯轉向非鴉片類藥物合併治療。醫療專業人員正系統性地以包括萘普生在內的治療方法取代鴉片類藥物單藥治療，以在不產生依賴性風險的情況下控制發炎。指引建議將非類固醇抗發炎藥（NSAIDs）列為第一線治療藥物，這直接推動了萘普生在鴉片類藥物減量框架中的應用。美國麻醉醫師協會（ASA）於2024年12月發布的最新數據也印證了這一趨勢，該數據題為《ASA就修訂版CDC疼痛管理鴉片類藥物處方指南的採納情況提供反饋》。報告顯示，約70%的醫生已調整其臨床實踐以符合安全指南，這表明非鴉片類替代療法的使用正在顯著增加。

同時，市場正在擴張，透過與網路藥局和數位醫療分銷管道的整合，患者的用藥途徑也得到了改善。各大電商平台正利用其物流網路提供處方箋止痛藥當日送達服務，滿足患者快速緩解疼痛的需求，無需前往實體藥局。這種數位化對依賴不間斷供應萘普生的行動患者尤其有利。近期公司的發展也印證了這種物流成長的規模。根據亞馬遜在2024年10月發布的新聞稿《亞馬遜藥局將當日配送服務擴展至20個城市》，該公司計劃到2025年在另外20個主要都會區推出處方箋藥當日配送，預計這將徹底改變人們獲取止痛藥的方式。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球萘普生市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 最終用途類別（緩解疼痛、抑制發炎、退燒、其他）
    • 銷售管道（直銷、間接銷售）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美萘普生市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲萘普生市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區萘普生市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：萘普生在中東和非洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：萘普生在南美洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球萘普生市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Jiangxi Tianxin Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Huazhong Pharmaceutical Co., Ltd（HPC）
  • Taj Pharmaceuticals Ltd.
  • Aurobindo Pharma Limited
  • Divi's Laboratories Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27628

The Global Naproxen Market is projected to expand from USD 227.82 Million in 2025 to USD 350.61 Million by 2031, reflecting a compound annual growth rate of 7.45%. Naproxen, a nonsteroidal anti-inflammatory drug, is predominantly prescribed to mitigate fever, inflammation, and pain linked to musculoskeletal disorders like tendonitis and arthritis. Market expansion is fueled by the escalating global prevalence of chronic pain conditions alongside a rapidly aging population that necessitates reliable analgesic options. This growth is further supported by the medication's economic viability and its broad accessibility in both over-the-counter and prescription forms. According to the Centers for Disease Control and Prevention, in 2024, approximately one in five adults in the United States was affected by arthritis, highlighting the urgent requirement for effective pain management solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 227.82 MIllion
Market Size 2031USD 350.61 MIllion
CAGR 2026-20317.45%
Fastest Growing SegmentDirect Sale
Largest MarketNorth America

However, the market's positive trajectory faces notable hurdles arising from the adverse health effects associated with extended usage. Significant concerns regarding gastrointestinal toxicity and cardiovascular complications continue to pose risks that reduce patient compliance and restrict the drug's long-term utility. These safety issues subsequently create opportunities for competing therapeutic classes to challenge naproxen's market standing.

Market Driver

The rising incidence of chronic inflammatory and musculoskeletal conditions serves as a primary engine for the Global Naproxen Market. The drug is widely adopted for treating ailments such as ankylosing spondylitis and osteoarthritis because of its effectiveness in alleviating stiffness and inflammation. Demand is further intensified by the enduring prevalence of lower back pain, which requires sustained management strategies. According to an article published in BMC Musculoskeletal Disorders in January 2025, titled 'Global, regional, and national burden of low back pain for adults aged 55 and older', roughly 271.7 million people in this demographic experienced low back pain worldwide. This substantial burden directly drives consistent sales volumes for both prescription and over-the-counter formulations as patients search for dependable relief.

Concurrently, the swift growth of the global geriatric population is a significant contributor to market expansion, given that older adults are more prone to joint degeneration. As life expectancies rise, the number of patients needing maintenance therapy for age-related conditions increases, cementing naproxen's status as an essential therapeutic option. According to the United Nations' 'World Population Prospects 2024' report released in July 2024, the global population aged 65 and older has reached approximately 830 million, establishing a massive patient base. This demographic trend translates into concrete financial results; for instance, Bayer reported in its 'Quarterly Statement Third Quarter of 2024' in November 2024 that its Consumer Health division achieved a 10.9% sales increase in the 'Pain & Cardio' category, highlighting the strong demand for analgesic products.

Market Challenge

The Global Naproxen Market confronts substantial obstacles stemming from documented health risks linked to long-term intake, particularly cardiovascular complications and gastrointestinal toxicity. This safety profile directly impedes market growth by limiting the medication's appropriateness for the prolonged management of chronic musculoskeletal disorders. Consequently, healthcare providers are exercising increased caution, frequently restricting dosage or treatment duration to minimize potential harm, which decreases the total volume of naproxen dispensed. Additionally, patient compliance often suffers as individuals become wary of these serious side effects, leading them to seek non-pharmacological interventions or alternative analgesic therapies.

Current clinical data further validates this hesitation by reinforcing the link between risk levels and dosage. According to the European Alliance of Associations for Rheumatology (EULAR) in 2024, the use of high-dose NSAIDs was correlated with a 10% increased risk of cardiovascular disease relative to lower doses. These findings highlight critical safety limitations that restrict the drug's commercial potential, forcing medical professionals to carefully balance therapeutic advantages against these risks, which ultimately suppresses revenue growth within the long-term pain management segment.

Market Trends

The market is increasingly characterized by a clinical shift toward non-opioid multimodal analgesia protocols. Medical professionals are systematically substituting opioid monotherapies with regimens that incorporate naproxen to manage inflammation without the risks of dependence. This transition, encouraged by guidelines promoting NSAIDs as first-line options, directly boosts the adoption of naproxen within opioid-sparing frameworks. Recent data supports this trend; according to the American Society of Anesthesiologists' article 'ASA Provides Feedback on the Uptake of the Revised CDC Guideline for Prescribing Opioids for Pain' published in December 2024, roughly 70% of physicians reported modifying their clinical practices to comply with safety guidelines, highlighting the movement toward non-opioid alternatives.

Simultaneously, the market is broadening its reach through integration with e-pharmacy and digital health distribution channels, which improves patient accessibility. Leading e-commerce platforms are leveraging logistics networks to provide same-day delivery for prescription pain relievers, meeting the demand for prompt relief without the need to visit a physical pharmacy. This digital advancement is especially beneficial for patients with limited mobility who depend on uninterrupted access to naproxen. The magnitude of this logistical growth is illustrated by recent corporate initiatives; according to an Amazon press release in October 2024 titled 'Amazon Pharmacy to Expand Same-Day Delivery to 20 More Cities', the company plans to launch same-day prescription delivery in 20 additional metropolitan areas by 2025, marking a lasting transformation in the acquisition of analgesic medications.

Key Market Players

  • Jiangxi Tianxin Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Huazhong Pharmaceutical Co., Ltd (HPC)
  • Taj Pharmaceuticals Ltd.
  • Aurobindo Pharma Limited
  • Divi's Laboratories Limited

Report Scope

In this report, the Global Naproxen Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Naproxen Market, By End-Use Application

  • Pain Relief
  • Inflammation Reduction
  • Fever Reduction
  • Others

Naproxen Market, By Sales Channel

  • Direct Sale
  • Indirect Sale

Naproxen Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Naproxen Market.

Available Customizations:

Global Naproxen Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Naproxen Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By End-Use Application (Pain Relief, Inflammation Reduction, Fever Reduction, Others)
    • 5.2.2. By Sales Channel (Direct Sale, Indirect Sale)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Naproxen Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By End-Use Application
    • 6.2.2. By Sales Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Naproxen Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By End-Use Application
        • 6.3.1.2.2. By Sales Channel
    • 6.3.2. Canada Naproxen Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By End-Use Application
        • 6.3.2.2.2. By Sales Channel
    • 6.3.3. Mexico Naproxen Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By End-Use Application
        • 6.3.3.2.2. By Sales Channel

7. Europe Naproxen Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By End-Use Application
    • 7.2.2. By Sales Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Naproxen Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By End-Use Application
        • 7.3.1.2.2. By Sales Channel
    • 7.3.2. France Naproxen Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By End-Use Application
        • 7.3.2.2.2. By Sales Channel
    • 7.3.3. United Kingdom Naproxen Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By End-Use Application
        • 7.3.3.2.2. By Sales Channel
    • 7.3.4. Italy Naproxen Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By End-Use Application
        • 7.3.4.2.2. By Sales Channel
    • 7.3.5. Spain Naproxen Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By End-Use Application
        • 7.3.5.2.2. By Sales Channel

8. Asia Pacific Naproxen Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By End-Use Application
    • 8.2.2. By Sales Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Naproxen Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By End-Use Application
        • 8.3.1.2.2. By Sales Channel
    • 8.3.2. India Naproxen Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By End-Use Application
        • 8.3.2.2.2. By Sales Channel
    • 8.3.3. Japan Naproxen Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By End-Use Application
        • 8.3.3.2.2. By Sales Channel
    • 8.3.4. South Korea Naproxen Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By End-Use Application
        • 8.3.4.2.2. By Sales Channel
    • 8.3.5. Australia Naproxen Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By End-Use Application
        • 8.3.5.2.2. By Sales Channel

9. Middle East & Africa Naproxen Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By End-Use Application
    • 9.2.2. By Sales Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Naproxen Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By End-Use Application
        • 9.3.1.2.2. By Sales Channel
    • 9.3.2. UAE Naproxen Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By End-Use Application
        • 9.3.2.2.2. By Sales Channel
    • 9.3.3. South Africa Naproxen Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By End-Use Application
        • 9.3.3.2.2. By Sales Channel

10. South America Naproxen Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By End-Use Application
    • 10.2.2. By Sales Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Naproxen Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By End-Use Application
        • 10.3.1.2.2. By Sales Channel
    • 10.3.2. Colombia Naproxen Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By End-Use Application
        • 10.3.2.2.2. By Sales Channel
    • 10.3.3. Argentina Naproxen Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By End-Use Application
        • 10.3.3.2.2. By Sales Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Naproxen Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Jiangxi Tianxin Pharmaceutical Co., Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Teva Pharmaceutical Industries Ltd.
  • 15.3. Huazhong Pharmaceutical Co., Ltd (HPC)
  • 15.4. Taj Pharmaceuticals Ltd.
  • 15.5. Aurobindo Pharma Limited
  • 15.6. Divi's Laboratories Limited

16. Strategic Recommendations

17. About Us & Disclaimer